Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
Plain-language summary
This NA trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide) (DRUG): 3 cycles of BvC treatment for all enrolled patients. Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.; Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.; | Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide) (DRUG): Consolidation therapy( For patients who achieved CR after induction therapy, 3 cycles of additional BvC treatment; For patients who achieved PR after induction therapy, 6 cycles of additional BvC treatment). Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.; Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.; Maintenance therapy chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years | Maintenance therapy-chidamide (DRUG): Chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years
- Drugs / treatments
- Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide), Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide), Maintenance therapy-chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details